Halil G. Guzel

Antalya, 06100, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

Journal: Cancers

Published: June 11, 2026

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.

Journal: BMC cancer

Published: June 04, 2026

Does Social Media Use Associate with Vasomotor, Sexual, and Musculoskeletal Symptoms in Breast Cancer Survivors Receiving Endocrine Therapy?

Does Social Media Use Associate with Vasomotor, Sexual, and Musculoskeletal Symptoms in Breast Cancer Survivors Receiving Endocrine Therapy?

Journal: Journal of clinical medicine

Published: April 12, 2026

Evaluation of the predictive and prognostic performance of the PILE score in metastatic renal cell carcinoma.

Evaluation of the predictive and prognostic performance of the PILE score in metastatic renal cell carcinoma.

Journal: Frontiers in medicine

Published: March 20, 2026

Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.

Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.

Journal: Journal of clinical medicine

Published: February 01, 2026

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkish Oncology Centers.

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkish Oncology Centers.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: January 28, 2026

Bone Metastasis Distribution Matters: Prognostic Effect of the Axial-to-Peripheral Ratio in Metastatic Hormone-Sensitive Prostate Cancer.

Bone Metastasis Distribution Matters: Prognostic Effect of the Axial-to-Peripheral Ratio in Metastatic Hormone-Sensitive Prostate Cancer.

Journal: The Prostate

Published: January 26, 2026

Pulmonary metastasectomy in colorectal cancer: the importance of interpreting neoadjuvant strategies in the era of modern systemic therapy.

Pulmonary metastasectomy in colorectal cancer: the importance of interpreting neoadjuvant strategies in the era of modern systemic therapy.

Journal: International journal of colorectal disease

Published: December 22, 2025

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study.

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study.

Journal: Therapeutic advances in medical oncology

Published: December 19, 2025

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study.

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study.

Journal: Cancers

Published: December 10, 2025

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 14, 2025

Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study.

Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study.

Journal: Cancer management and research

Published: October 15, 2025

Showing 1-12 of 38

Last Updated: 09/26/2026